Navigation Links
Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
Date:4/8/2013

CAMBRIDGE, Mass., April 8, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel therapy MM-121 restores tumor sensitivity and delays the onset of resistance to the aromatase inhibitor, letrozole, in an ER+ breast cancer model. The study was presented as part of the American Association for Cancer Research's 2013 Annual Meeting in Washington, DC, April 6-10, 2013.

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival. By inhibiting ErbB3 signaling, MM-121 was found to restore sensitivity, delay resistance and enhance the anti-tumor effect of letrozole as a combination therapy partner.

"In nearly all cases of advanced ER+ breast cancer, endocrine therapies are initially effective, but patients eventually develop resistance to these treatments," said Gavin MacBeath , Co-Founder and Head of Translational Research, Merrimack Pharmaceuticals. "We are excited to see that in preclinical models, MM-121 blocked activation of its target, ErbB3, and down-regulated several signaling pathways within these tumors.  We saw delayed resistance to letrozole when co-administered with the drug, and restored sensitivity when added after the tumors developed resistance to letrozole. These data help guide our thinking regarding how best to combine MM-121 with anti-hormonal therapies in the treatment of advanced ER+ breast cancer."

Study Methodology
The activity of MM-121 alone and in combination with letrozole was measured in an MCF7 in vivo model of post-menopausal ER+ breast cancer engineered to express aromatase. Models of ER+ breast cancer were randomized to receive letrozole, MM-121 or both MM-121 and letrozole following development of resistance to letrozole. Tumor
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
2. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
3. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
4. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
5. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
6. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
7. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
8. Valeant Pharmaceuticals Provides Update to Recent Event
9. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
10. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
11. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  As physicians ... to digital communication channels to learn about new ... finding – from a new report by global ... – shows that communicating via a customized mix ... provides the best opportunity to engage with physicians. ...
(Date:9/23/2014)... -- Enable Injections , developer of a novel ... and nearly painless for patients to self-inject large-dose biologic ... named winner of the ,Buzz of BIO Investor Forum, ... Enable is one of only two ,Buzz ... votes in the "Late Stage Leaders" category.  ...
(Date:9/23/2014)... 2014 Avillion LLP, a ... of Jarrod Longcor as Chief Business ... for structuring, negotiating and executing successful strategic alliances, ... providing management and strategic leadership to the organisation. ... team. Mr Longcor brings to Avillion ...
Breaking Medicine Technology:As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... Intra-Cellular Therapies, Inc. (ITI),today announced it has initiated ... using its drug candidate ITI-722. ITI-722 acts predominantly,as ... important new,approach to the treatment of SMI. Because ... modulatory activities, ITI believes, ITI-722 can be,used not ...
... Research Is a Winning Pursuit, WASHINGTON, Dec. ... L. Trull President, Foundation for Biomedical,Research:, Biomedical ... of pursuit" in 1980 earned Mario Capecchi a ... setback, the Harvard-educated genetics professor,persisted toward his goal. ...
Cached Medicine Technology:Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 2Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 3Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 4Nobel Prize-Winning Discovery 2Nobel Prize-Winning Discovery 3
(Date:9/23/2014)... The Fit Body Boot Camp franchise is known throughout ... and their community outreach. The new Rockville Fit Body Boot ... of the company’s new fitness boot camp in ... is excited about the grand opening, because of the opportunity ... honor the memory of emergency workers who sacrificed their lives ...
(Date:9/23/2014)... 2014 Maturo Medical Weight and ... announced Dr. Lisa Maturo has received certification in ... Worldlink Medical Academy. Dr. Maturo is one of ... this credential. , World-renowned bioidentical hormone replacement ... the rigorous training course, which trained participants in ...
(Date:9/23/2014)... 23, 2014 Wohl Associates ... packaging equipment, has recently taken delivery of used industrial ... include mixers, sheeters, and equipment for producing gnocchi and ... Toresani unit and a La Parmigiana mixer/extruder. With a ... a mixing tank that is 17” wide, 28” long ...
(Date:9/23/2014)... 23, 2014 Hope For The Warriors® ... Celebration to be hosted in Boston, Massachusetts on Sunday, ... Amphitheater. This signature event honors the courage of our ... the fallen. Proceeds from the evening will benefit Hope ... a sense of self, restoring the family unit, and ...
(Date:9/23/2014)... Los Angeles, CA (PRWEB) September 23, 2014 ... launched sales funnel building software application has created a ... commotion surrounding the launch of this new software has ... published an investigative review for her readers. ... such as site design, programming and development can be ...
Breaking Medicine News(10 mins):Health News:Rockville Fit Body Boot Camp Invites Community to Fitness Boot Camp Grand Opening 2Health News:Rockville Fit Body Boot Camp Invites Community to Fitness Boot Camp Grand Opening 3Health News:Doctor Lisa Maturo of Maturo Medical Obtains Expert Certification in BioIdentical Hormone Replacement Therapy from World Link Medical 2Health News:Used Industrial Pasta Machinery Now Available at Wohl Associates 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3Health News:ClickFunnels 2.0 – Review Of Russell Brunson’s Sales Funnel Building Software Released 2
... Group,Inc. (Amex: QGP ) (http://www.QuantumMD.com ), ... Noel J. Guillama, President &,CEO, will present at ... p.m. (Pacific) on Monday, August 18, 2008 at ... Guillama will give a 23-minute presentation regarding The ...
... a national survey,of adults, 60 percent of Hispanic American ... is the #1 fatal disease among women.,Further, nearly half ... greater than that of Caucasian women. Dania Rich-Spencer, Vice,President ... the Go,Red For Women, founded by the American Heart ...
... getting infected cells to drop their guard according to ... a catalyst to a cancer-busting reaction which calls up an ... Cancer adapts quickly to traditional drugs which attack infected cells ... of defence using ruthenium as a catalyst to a reaction ...
... School of Medicine, Fox Chase Cancer Center and ... that will speed the translation of medical and ... , As part of the agreement, the ... Translational Medicine, based at Temple, to design and ...
... Program to Increase Breast and ... Cervical Cancer Screening Rates, COLUMBIA, ... care guidance company, today announced the,launch of their Women,s Health ... to help increase the,prevention and early detection of breast and ...
... all evidence of disease in selected patients with cancer ... the first published report from an ongoing clinical trial. ... Clinical Cancer Research, (published online August 12) researchers ... targeted radiation therapy had completely controlled all signs of ...
Cached Medicine News:Health News:The Quantum Group to Present at the Noble Financial Equity Conference 2Health News:The Quantum Group to Present at the Noble Financial Equity Conference 3Health News:Temple, Fox Chase and Geisinger create Keystone Institute for Translational Medicine 2Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 2Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 3Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 4Health News:Targeted radiation therapy can control limited cancer spread 2Health News:Targeted radiation therapy can control limited cancer spread 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: